Edition:
Deutschland

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

186.37USD
6 Dec 2019
Change (% chg)

$0.29 (+0.16%)
Prev Close
$186.08
Open
$186.40
Day's High
$186.88
Day's Low
$186.23
Volume
382,938
Avg. Vol
744,014
52-wk High
$186.90
52-wk Low
$114.27

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Buy/Sell

Sell Hold Buy
2.74 Mean rating from 19 analysts

Overall

Beta: 1.64
Market Cap(Mil.): $61,181.05
Shares Outstanding(Mil.): 328.28
Dividend: 0.74
Yield (%): 1.59

PRESS DIGEST- Financial Times - Nov 13

Nov 13 Here are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.

Photo

AbbVie 2019 revenue forecast tops Wall Street estimates while it eyes future Botox sales

AbbVie Inc on Friday forecast 2019 revenue above Wall Street estimates and expressed confidence in future sales of blockbuster wrinkle treatment Botox, which it will acquire with its $63 billion purchase of Allergan Plc .

Photo

AbbVie 2019 revenue forecast tops Wall Street estimates while it eyes future Botox sales

AbbVie Inc on Friday forecast 2019 revenue above Wall Street estimates and expressed confidence in future sales of blockbuster wrinkle treatment Botox, which it will acquire with its $63 billion purchase of Allergan Plc .

UPDATE 2-AbbVie 2019 revenue forecast tops Wall Street estimates while it eyes future Botox sales

Nov 1 AbbVie Inc on Friday forecast 2019 revenue above Wall Street estimates and expressed confidence in future sales of blockbuster wrinkle treatment Botox, which it will acquire with its $63 billion purchase of Allergan Plc.

Photo

AbbVie says multiple parties vying for assets related to Allergan deal approval

AbbVie Inc said on Friday it was in talks with several parties interested in buying the two assets it intends to divest for the completion of its $63 billion deal to buy drugmaker Allergan Plc .

AbbVie says multiple parties vying for assets related to Allergan deal approval

Nov 1 AbbVie Inc said on Friday it was in talks with several parties interested in buying the two assets it intends to divest for the completion of its $63 billion deal to buy drugmaker Allergan Plc.

AbbVie lifts 2019 profit forecast as Humira helps beat revenue estimates

Nov 1 AbbVie Inc posted quarterly sales above estimates on Friday and raised the lower end of its 2019 profit forecast, helped by strong demand for cancer medicine Imbruvica and a lower-than-expected drop in bestseller Humira's revenue.

RPT-UPDATE 1-Allergan settles Alzheimer's therapy lawsuit for $750 million

Oct 28 Allergan Plc would pay $750 million to settle a class action lawsuit from a group of direct purchasers of Alzheimer's disease therapy Namenda, the drugmaker said, in a resolution to the litigation that was set to face trial on Monday.

Allergan settles Alzheimer's therapy lawsuit for $750 million

Oct 28 Allergan Plc said on Monday it had settled a class action lawsuit brought by a group of direct purchasers of Alzheimer's disease therapy Namenda, resolving the litigation that was set to face trial this month.

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie +0.68%
Rohstoffe +0.93%
Industrie +0.59%
Konjunktur abhängige Waren & Dienstleistungen +0.56%
Konjunktur unabhängige Waren & Dienstleistungen +0.87%
Finanzindustrie +0.54%
Pharma +0.97%
Technologie +0.28%
Telekommunikation -0.03%

Nachrichten aus der Wirtschaft

Photo

Schweizer Börse legt zu - Swiss Re nach Spartenverkauf gesucht

Zürich Gute US-Konjunkturdaten haben der Schweizer Börse zum Wochenschluss Schub verliehen. Der SMI gewann rund ein Prozent auf 10.463 Punkte. Der stärkste Stellenaufbau in den USA seit zehn Monaten zeigte Händler zufolge, dass der US-Arbeitsmarkt in besserer Verfassung ist erwartet. Trotz des Schlussspurts verbuchte der Leitindex im Verlauf der gesamten Woche ein Minus von rund 0,3 Prozent.